New York, US, Liver disease biotech company Ochre Bio have appointed Mark Lundquist, PhD, MBA, as Head of Late Stage Validation and site lead for their New York City lab.
Dr. Lundquist is an experienced oncology and immuno-oncology R&D leader, having previously held roles as Head of Biology and Pharmacology at Alphina Therapeutics and Senior Scientist at Kadmon Holdings. He has a BSE from the University of Pennsylvania, a Masters in Biotechnology from John Hopkins University, a PhD in Pharmacology from the Weill Cornell Graduate School of Medical Sciences and an MBA from Columbia Business School.
In his new role with Ochre Bio, Dr. Lundquist takes on responsibility for running the company’s highly unique organ perfusion lab, which deep phenotypes human livers perfused on machines to study their responses to advanced RNA therapies.
This is a milestone hire for Ochre Bio and a significant addition to the senior leadership team, coming at a pivotal moment in the company’s growth. Dr. Lundquist joins the company just months after the signing of two multi-million dollar partnership deals with GSK and with Boehringer Ingelheim.
Mark Lundquist, Incoming Head of Late Stage Validation at Ochre Bio, said:
“Late stage liver diseases affect millions of patients worldwide, yet approved treatment options remain limited. I look forward to innovating and working with other Ochre teams to develop new technologies and pipelines in pursuit of addressing major liver health challenges”.
Kenny Moore, Head of R&D at Ochre Bio, said:
“Built on decades of leading genomics, drug discovery and development experience, Ochre Bio’s scientific teams are committed to addressing unmet needs for patients with late stage liver disease globally. Mark brings a wealth of experience in R&D leadership and in driving biotech innovation, making him a strong and welcome addition to our team.”
